Ad-NK4 gene therapy (Chiba Cancer Center Res Inst/Toho University/Tokyo Women’s Medical University Yachiyo Medical Center)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameAd-NK4 gene therapy (Chiba Cancer Center Res Inst/Toho University/Tokyo Women’s Medical University Yachiyo Medical Center)
Drug Alias NameNK4 gene therapy (Chiba Cancer Center Res Inst/Toho University/Tokyo Women’s Medical University Yachiyo Medical Center)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionHepatocyte growth factor receptor inhibitors
TargetsHepatocyte growth factor receptor
Therapy Area/IndicationsMesothelioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesChiba Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesTokyo Women's Medical CollegeChiba Cancer CenterToho University
Inactive CompaniesN/A
Active IndicationsMesothelioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A